

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Takayuki YOSHIOKA et al. :
Serial No. NEW : **Attn: APPLICATION BRANCH**
Filed December 11, 2003 : Attorney Docket No. 2003_1801

OXADIAZOLE DERIVATIVES HAVING
ANTICANCER EFFECTS
(Rule 1.53(b) Divisional
of Serial No. 10/257,917,
Filed October 18, 2002)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of ☒ the references listed on attached form PTO-1449 and/or ☐ the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No. 10/257,917.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or


b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page ,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Takayuki YOSHIOKA et al.

By 
Matthew M. Jacob
Registration No. 25,154
Attorney for Applicants

MJ/da
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
December 10, 2003

FORM PTO 1449 (modified)

ATTY DOCKET NO.
2003_1801SERIAL NO.
NEWU.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: December 10, 2003

APPLICANT
Takayuki YOSHIOKA et al.FILING DATE
December 11, 2003

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,423,729	7/2002	Kurihara			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AB	1029541	8/2000	EP			Abstract	
	AC	00/15213	3/2000	WIPO			Abstract	
	AD							
	AE							
	AF							

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AG	Whittaker et al, <i>Chemical Reviews</i> , Vol. 99, No. 9, pages 2735-2776, (1999)						
	AH	Michaelides et al, <i>Current Pharmaceutical Design</i> , Vol. 5, pages 787-819, (1999)						
	AI	Stearns et al, <i>Cancer Research</i> , Vol. 53, pages 878-883, (1993)						
	AJ	Davies et al, <i>Cancer Research</i> , Vol. 53, pages 5365-5369, (1993)						
	AK	Sarén et al, <i>The Journal of Immunology</i> , Vol. 157, pages 4159-4165, (1996)						
	AL	Johnatty et al, <i>The Journal of Immunology</i> , Vol. 158, pages 2327-2333, (1997)						

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.